Evidence map›Paper›PMID 26774565›Full record

ArticleBiomaterials2016

Fibromodulin reprogrammed cells: A novel cell source for bone regeneration.

Chen-Shuang Li, Pu Yang, Kang Ting, Tara Aghaloo, Soonchul Lee, Yulong Zhang, Kambiz Khalilinejad, Maxwell C Murphy, Hsin Chuan Pan, Xinli Zhang and 5 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Biomaterials, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.

0numbers the graph read from it
0cells of the map it votes in
21citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

21 citing papers in PubMed.

  1. Article
  2. Article
  3. Biomimetic strategies for the deputization of proteoglycan functions.Frontiers in cell and developmental biology · 2024
    Review
  4. Article
  5. Article
  6. Article
  7. Review
  8. Review
  9. Article
  10. Review
  11. Review
  12. Article
  13. Article
  14. Review
  15. Article
  16. Review
  17. Dipyridamole enhances osteogenesis of three-dimensionally printed bioactive ceramic scaffolds in calvarial defects.Journal of cranio-maxillo-facial surgery : official publication of the European Association for Cranio-Maxillo-Facial Surgery · 2018
    Article
  18. Tendinopathy: injury, repair, and current exploration.Drug design, development and therapy · 2018
    Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Chen-Shuang LiDental and Craniofacial Research Institute and Division of Growth and Development, Section of Orthodontics, School of Dentistry, University of California, Los Angeles, Los Angeles, CA, 90095, USA; Department of Orthodontics, Peking University School and Hospital of Stomatology, Beijing, 100081, PR China.
Pu YangDental and Craniofacial Research Institute and Division of Growth and Development, Section of Orthodontics, School of Dentistry, University of California, Los Angeles, Los Angeles, CA, 90095, USA; State Key Laboratory of Oral Diseases, West China Hospital of Stomatology, Sichuan University, Chengdu, 610041, PR China.
Kang TingDental and Craniofacial Research Institute and Division of Growth and Development, Section of Orthodontics, School of Dentistry, University of California, Los Angeles, Los Angeles, CA, 90095, USA.
Tara AghalooDental and Craniofacial Research Institute and Division of Growth and Development, Section of Orthodontics, School of Dentistry, University of California, Los Angeles, Los Angeles, CA, 90095, USA.
Soonchul LeeDental and Craniofacial Research Institute and Division of Growth and Development, Section of Orthodontics, School of Dentistry, University of California, Los Angeles, Los Angeles, CA, 90095, USA; Department of Orthopaedic Surgery, CHA Bundang Medical Center, CHA University, Gyeonggi-do, 463-712, South Korea.
Yulong ZhangDepartment of Bioengineering, University of California, Los Angeles, Los Angeles, CA, 90095, USA.
Kambiz KhalilinejadDental and Craniofacial Research Institute and Division of Growth and Development, Section of Orthodontics, School of Dentistry, University of California, Los Angeles, Los Angeles, CA, 90095, USA.
Maxwell C MurphyDental and Craniofacial Research Institute and Division of Growth and Development, Section of Orthodontics, School of Dentistry, University of California, Los Angeles, Los Angeles, CA, 90095, USA.
Hsin Chuan PanDental and Craniofacial Research Institute and Division of Growth and Development, Section of Orthodontics, School of Dentistry, University of California, Los Angeles, Los Angeles, CA, 90095, USA.
Xinli ZhangDental and Craniofacial Research Institute and Division of Growth and Development, Section of Orthodontics, School of Dentistry, University of California, Los Angeles, Los Angeles, CA, 90095, USA.
Benjamin WuDepartment of Bioengineering, University of California, Los Angeles, Los Angeles, CA, 90095, USA.
Yan-Heng ZhouDepartment of Orthodontics, Peking University School and Hospital of Stomatology, Beijing, 100081, PR China.
Zhihe ZhaoState Key Laboratory of Oral Diseases, West China Hospital of Stomatology, Sichuan University, Chengdu, 610041, PR China.
Zhong ZhengDental and Craniofacial Research Institute and Division of Growth and Development, Section of Orthodontics, School of Dentistry, University of California, Los Angeles, Los Angeles, CA, 90095, USA. Electronic address: zzheng@dentistry.ucla.edu.
Chia SooUCLA Division of Plastic Surgery and Department of Orthopaedic Surgery and the Orthopaedic Hospital Research Center, University of California, Los Angeles, Los Angeles, CA, 90095, USA. Electronic address: bsoo@ucla.edu.

Funding

UCLA Clinical and Translational Science InstituteUL1TR000124 · NCATS · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI DUBINETT, STEVEN M. · 2012 to 2015
$57.0M
Novel peptide-impregnated hydrogel as a wound healing deviceR44DE026080 · NIDCR · SCARLESS LABORATORIES, INC. · PI SOO, CHIA, ZHENG, ZHONG · 2016 to 2023
$4.7M
Anti-scar peptide for cleft lip repairR44DE024692 · NIDCR · SCARLESS LABORATORIES, INC. · PI SOO, CHIA, ZHENG, ZHONG · 2014 to 2016
$1.5M
A novel anti-scar peptide for cutaneous wound repairR44AR064126 · NIAMS · SCARLESS LABORATORIES, INC. · PI SOO, CHIA, ZHENG, ZHONG · 2015 to 2016
$1.5M
NCATS NIH HHS UL1 TR000124NCATS NIH HHS UL1TR000124NIAMS NIH HHS R44 AR064126NIAMS NIH HHS R44AR064126NIDCR NIH HHS R44 DE024692NIDCR NIH HHS R44DE024692NIDCR NIH HHS R44 DE026080PHS HHS CJX1-443835-WS-29646
6 · The paper itself

Abstract

Pluripotent or multipotent cell-based therapeutics are vital for skeletal reconstruction in non-healing critical-sized defects since the local endogenous progenitor cells are not often adequate to restore tissue continuity or function. However, currently available cell-based regenerative strategies are hindered by numerous obstacles including inadequate cell availability, painful and invasive cell-harvesting procedures, and tumorigenesis. Previously, we established a novel platform technology for inducing a quiescent stem cell-like stage using only a single extracellular proteoglycan, fibromodulin (FMOD), circumventing gene transduction. In this study, we further purified and significantly increased the reprogramming rate of the yield multipotent FMOD reprogrammed (FReP) cells. We also exposed the 'molecular blueprint' of FReP cell osteogenic differentiation by gene profiling. Radiographic analysis showed that implantation of FReP cells into a critical-sized SCID mouse calvarial defect, contributed to the robust osteogenic capability of FReP cells in a challenging clinically relevant traumatic scenario in vivo. The persistence, engraftment, and osteogenesis of transplanted FReP cells without tumorigenesis in vivo were confirmed by histological and immunohistochemical staining. Taken together, we have provided an extended potency, safety, and molecular profile of FReP cell-based bone regeneration. Therefore, FReP cells present a high potential for cellular and gene therapy products for bone regeneration.

Indexed as

AnimalsBone RegenerationCell DifferentiationCells, CulturedCell TransplantationCellular ReprogrammingCHO CellsCricetinaeCricetulusCulture MediaExtracellular Matrix ProteinsFibromodulinGene Expression RegulationHumansImmunohistochemistryMaleCulture MediaExtracellular Matrix ProteinsFibromodulinMineralsProteoglycansDifferentiationFibromodulin (FMOD)Fibromodulin reprogrammed (FReP) cellsOsteogenesisReprogramming

Identifiers

PMID26774565
PMCPMC4754141

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.